Fluidigm Corporation (NASDAQ:FLDM) has begun direct service to customers in China. Through the establishment of a wholly-owned Fluidigm subsidiary in China in late January 2012, officially known as Fluidigm (Shanghai) Instrument Technology Co., Ltd. or 富鲁达(上海)仪器科技有限公司, Fluidigm will improve services to its Chinese customer base and expects to rapidly build a strong presence in that country’s burgeoning life science research community.
“The establishment of our China subsidiary in this rapidly growing nation is an especially important commercial development for Fluidigm. We believe China will be an important growth driver for Fluidigm in 2012 and into the future,” said Gajus Worthington, president and chief executive officer of Fluidigm. “China is aggressively pursuing research in therapeutic stem cells and single-cell genomics. Customers in various Chinese universities, hospitals and government-sponsored laboratories are conducting world-class research in these areas of global importance and they need world-class tools to help them achieve their objectives. We believe Fluidigm nanofluidic technology brings the world’s most advanced single-cell and stem-cell solutions available in the world to the Chinese life science research community. We want to help our customers move forward in these critical areas of research as quickly as possible,” Worthington concluded.
“Over the years, we have sold and installed more than 20 instruments in China. Those systems are helping our customers conduct single-cell research, prepare samples for targeted sequencing experiments, and ensure the quality and safety of China’s food supply. This is a good beginning and we hope to contribute more capabilities to the Chinese research community in the future,” said Joanna Jiang, general manager of Fluidigm China. “While we now have a direct presence in China, we are a small company and will continue to work with our distribution partners to ensure that we can meet the needs of our customers throughout China’s vast geography.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV